Clinical trial · Interventional
Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors
A Multicenter, Open-Label, Phase Ib/II Trial of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors
NCT04856774CI-TRIAL-00078349completedPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main purpose of this study was to assess the safety, tolerability, and efficacy when combining SHR-1701 and BP102 in participants with certain cancers. This study was conducted in 2 phases, Phase Ib and Phase II.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Solid Tumors | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| SHR-1701；BP102 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- SHR -1701 + BP102
- interventionNames
- Drug: SHR-1701；BP102
Primary outcomes (2)
- measure
- recommended phase 2 dose (Phase Ib)
- timeFrame
- At the end of Cycle 2 (each cycle is 21 days)
- measure
- Objective response rate (ORR)
- timeFrame
- 2 years
Secondary outcomes (9)
- measure
- Dose Limiting Toxicity (DLT) (Phase 1b)
- timeFrame
- At the end of Cycle 2 (each cycle is 21 days)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Histologically or cytologically confirmed solid malignancy that is metastatic or unresectable for which standard curative or palliative measures do not exist or are no longer effective (phase Ib) 2. Histologically or cytologically confirmed metastatic or locally advanced solid tumors of the selected indications. (Phase II). 3. .Life expectancy exceeds 12 weeeks; 4. The Eastern Cancer Cooperative Group (ECOG) has a performance score of 0 or 1; 5. Normal organ and marrow function; Exclusion Criteria: 1. Has known active central nervous system (CNS) metastases. Subjects with previously treated brain metastases may participate provided they are stable. 2. A history of human immunodeficiency virus (HIV) infection is known, or has an active autoimmune disease. 3. History of interstitial lung disease or pneumonia requiring oral or intravenous steroids. 4. Has moderate or severe cardiovascular disease; 5. Active HBV(hepatitis B) or HCV (Hepatitis C virus)-infected subjects; 6. Any other malignancies within 5 years except for those with negligible risk of metastasis or death.
References
Publications (0)
Data not yet available
No reference posted for this study.